NASDAQ:CTMX
CytomX Therapeutics Stock News
$2.18
-0.0100 (-0.457%)
At Close: Mar 28, 2024
Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2022
03:53pm, Monday, 11'th Jul 2022 Benzinga
Upgrades
For Visteon Corp (NASDAQ:VC), Exane BNP Paribas upgraded the previous rating of Neutral to Outperform. For the first quarter, Visteon had an EPS of $1.09, compared to year-ago quarter EPS of
This Low-Float Stock Jumps Around 148%; Here's 64 Biggest Movers From Yesterday
08:15am, Friday, 08'th Jul 2022 Benzinga
Gainers
United Maritime Corporation (NASDAQ: USEA) climbed 147.6% to close at $7.08 on Thursday on heavy momentum following the company's recent listing on the Nasdaq Capital Market.
Grove Collabora
Nasdaq Surges 250 Points; Crude Oil Rises Sharply
07:01pm, Thursday, 07'th Jul 2022 Benzinga
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite jumping 250 points following the release of data on initial jobless claims.
The Dow traded up 1.04% to 31,359.65 while th
Dow Jumps More Than 200 Points; Samsung Sees This Much Surge In Quarterly Revenue
04:11pm, Thursday, 07'th Jul 2022 Benzinga
U.S. stocks traded higher midway through trading, with the Dow Jones jumping more than 200 points following the release of data on initial jobless claims.
The Dow traded up 0.77% to 31,275.90 while th
This EV Maker Stock Jumps More Than 9%, Here's 46 Stocks Moving In Thursday's Mid-Day Session
04:02pm, Thursday, 07'th Jul 2022 Benzinga
Gainers
United Maritime Corporation (NASDAQ: USEA) jumped 180.4% to $8.02. The company’s stock jumped 190% on Wednesday after completing its spin-off from Seanergy Maritime Holdings Corp.
American
Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022
02:04pm, Thursday, 07'th Jul 2022 Benzinga
Upgrades
For Pacific Premier Bancorp Inc (NASDAQ:PPBI), Raymond James upgraded the previous rating of Outperform to Strong Buy. In the first quarter, Pacific Premier Bancorp showed an EPS of $0.70, co
This Analyst Cuts Price Target On Microsoft; Here's The Biggest Price Target Changes For Thursday
11:53am, Thursday, 07'th Jul 2022 Benzinga
Truist Securities cut Criteo S.A. (NASDAQ: CRTO) price target from $40 to $35. Criteo shares fell 3.5% to close at $22.92 on Wednesday.
Barclays raised Eli Lilly and Company (NYSE: LLY) price targ
Why Is GameStop Surging By Around 10%? 22 Stocks Moving In Thursday's Pre-Market Session
10:25am, Thursday, 07'th Jul 2022 Benzinga
Gainers
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 39.6% to $0.2471 in pre-market trading after declining over 8% on Wednesday. Allena Pharmaceuticals recently announced rescheduling of special
U.S. Stock Futures Edge Higher After Fed Minutes
09:07am, Thursday, 07'th Jul 2022 Benzinga
Pre-open movers
U.S. stock futures traded slightly higher in early pre-market trade on Thursday following the release of Wednesday’s Fed meeting minutes, suggesting inflation remains the central ban
CytomX's Breast Cancer Candidate Meets Primary Goal Of Objective Response Rate
06:32am, Thursday, 07'th Jul 2022
CytomX Therapeutics Inc's (NASDAQ: CTMX) Phase 2 study of praluzatamab ravtansine in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-non-amplified breast cancer (Arm A
CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer
08:05pm, Wednesday, 06'th Jul 2022 GlobeNewswire Inc.
- Study meets primary endpoint of objective response rate in HR+/HER2-non-amplified breast cancer -
NeoGenomics (NEO) Surges 6.4%: Is This an Indication of Further Gains?
12:33pm, Monday, 27'th Jun 2022 Zacks Investment Research
NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CytomX Therapeutics to Present at Jefferies 2022 Global Healthcare Conference
08:00am, Wednesday, 01'st Jun 2022
SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that
CytomX Therapeutics' (CTMX) CEO Sean McCarthy on Q1 2022 Results - Earnings Call Transcript
03:17pm, Saturday, 07'th May 2022
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Chau Cheng - VP, IR & Corporate Communications Sean McCarthy - CEO & Chairman Amy
CytomX Therapeutics (CTMX) Q1 2022 Earnings Call Transcript
02:30am, Saturday, 07'th May 2022 The Motley Fool
CTMX earnings call for the period ending March 31, 2022.